Original Articles
Vol. 17 No. 2 (2023)
Association of TNF-α, IFN-γ, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 18 July 2023
1586
Views
614
Downloads
81
HTML
Authors
Cytokines have a crucial part in the pathogenesis, persistence of infection, and prognosis of hepatitis B virus (HBV) infection as HBV does not cause direct liver destruction; rather, disease-related complications and prognosis are more associated with immune system action, specifically cytokines such as TNF-α, IFN-γ, IL-6, IL-10, and other cytokines. This study sought to link TNF-, IFN-, IL-6, and IL-10 to various clinical manifestations of HBV infection. Ninety sera were taken from HBV-infected patients, 30 (33.3%) of whom had liver cirrhosis, 30 (33.3%) were HBV carriers, 19 (21.2%) were acute HBV patients, and 11 (12.2%) were recently HBV infected. ELISA was used to determine the serum levels of TNF-α, IFN-γ, IL-6, and IL-10. HBV-infected patients with liver cirrhosis had considerably higher mean serum levels of IFN-γ (P=0.005) and IL-10 (P=0.003), but TNF-α and IL-6 were significantly higher in recent HBV-infected patients (P values 0.034 and 0.004, respectively). There were substantial changes in mean serum levels of TNF-α, IFN-γ, IL-6, and IL-10 at different phases of HBV infection, implying a role for cytokines in HBV etiology, chronicity, and consequences.
Downloads
Download data is not yet available.
Citations
Wong DJ, Locarnini SA, Thompson AJV. Hepatitis B virus. In Richman DD, Whitley RJ, Hayden FG. Clinical virology, 4th ed. ASM Press. Washington DC, USA. 2017;713-70.
Sheron N, Lau J, Daniels H, et al. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol 1991;12:241-5.
Cagri BA, Buke M, Altuglu IE, et al. Tumor Necrosis Factor Alpha and Interleukin 6 Productions in Response to Platelet-Activating Factor in Chronic Hepatitis B Virus Infection. J Med Princ Pract 2004;13:273-6.
Bilgic Y, Seckin Y, Cagin YF, et al. Does the tumor necrosis factor a predictor factor in patients with chronic hepatitis B and C. J Biomed Res 2017;28:1683-7.
Lau JY, Bain VG, Naoumov NV, et al. Effect of interferon-gamma on hepatitis B viral antigen expression in primary hepatocyte culture. J Hepatol 1991;14:975-9.
Xia C, Liu Y, Chen Z, Zheng M. Involvement of Interleukin-6 in Hepatitis B Viral Infection. Cell Physiol Biochem 2015;37:677-86.
Tang S, Liu Z, Zhang Y, et al. Rather than rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese han population. Dis Markers 2013;35:799-805.
Luo MX, Wong SH, Chan MT, et al. Autophagy mediates hbx-induced nuclear factor-kappab activation and release of il-6, il-8, and cxcl2 in hepatocytes. J Cell Physiol 2015;230:2382-2389.
Chau G, Wu C, Lui W, et al. Serum interleukin IL-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552-8.
Fioravanti J, Lucia PD, Magini D, et al. Effector CD8 + T cell-derived interleukin-10 enhances acute liver immunopathology. J Hepatol 2017;67:543-8.
Weng HL, Cai MW, Wang BE, et al. Clinical study of anti-hepatic fibrosis effect of INF-gamma in patients with chronic hepatitis B. Chin Med J 2003;83:943-47.
Weng HL, Wang BE, Jia JD, et al. Effect of interferongamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. J Clin Gastroenterol Hepatol 2005;3:819-28.
Wu YJ, Cai MW, Li Q, et al. Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection. Hepatobiliary Pancreat Dis Int J 2011;10:151-7.
Matskevich AA, Cordelier P, Strayer DS. Conditional expression of INF-alpha and INF-gamma activated by HBV as genetic therapy for hepatitis B. J Interferon Cytokine Res 2003;23:709-21.
Paul S, Tabassum S, Islam MN. Interferon-gamma (INFgamma) response to different hepatitis B virus antigens in hepatitis B infection. J Bangladesh Med Rese Counc Bull 2004;30:72-7.
Quancheng K, Duolu Li, Zujiang Y. Specific expression of human interferon-gamma controls hepatitis B virus replication in vitro in secreting hepatitis B surface antigens hepatocytes. J Virol Methods 2012;180:84-90.
Wieland SF, Vega RG, Müller R, et al. Searching for interferon- induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 200;7:1227-36.
Toyonaga T, Hinot O, Sugai S, et al. Chronic active hepatitis in transgenic mice expressing interferon-y in the liver. Proc Natl Acad Sci USA 1994;91:614-8.
Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. J Clin Transl Immunol 2016;5:e115.
Nobili L, Albani L, Gabrielli A, Moroncini G. Reactivation of Hepatitis B Virus Infection Associated with Anti-Tumor Necrosis Factor-α Therapy. J Antivir Antiretrovir 2014;6:92-101.
Biermer M, Puro R, Schneider RJ. Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-β. J Virol 2003;77:4033-42.
Tzeng HT, Tsai HF, Chyuan IT, et al. Tumor Necrosis Factor-Alpha Induced by Hepatitis B Virus Core Mediating the Immune Response for Hepatitis B Viral Clearance in Mice Model. PLoS ONE 2014;9:e103008.
Bouezzedine F, Fardel O, Gripon P. Interleukin 6 inhibits HBV entry through NTCP down-regulation. Virol J 2015;481:34-42.
Palumbo GA, Scisciani C, Pediconi N, et al. IL-6 Inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLOS ONE 2015;10:e0142599.
Galun E, Nahor O, Eid A, et al. Human Interleukin-6 Facilitates Hepatitis B Virus Infection in Vitro and in Vivo. J Virol 2000;270:299-309.
Lan T, Chang L, Wu L, Yuan Y. IL-6 Plays a Crucial Role in HBV Infection. J Clin Transl Hepatol 2015;3:271-6.
Zhang F, Yao S, Zhang M, et al. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis 2011;15:e267-e271.
Tülek N, Saglam Sk, Saglam M, et al. Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection. J Hepatogastroenterol 2000;47:828-31.
Wang K, Wu Z, Ye Y, et al. Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. J Hepat Mon 2014;14:e19370.
Nabioullin R, Sone S, Mizuno K, et al. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol 1994;55:437-42.
Hyodo N, Nakamura I, Imawari M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. J Clin Exp Immunol 2004;135:462-6.
Ӧzgüler M, Akbulut HH, Akbulut A. Evaluation of Interleukin-10 Levels in Patients Diagnosed with Chronic Hepatitis. West Indian Med J 2015;64:71-5.
How to Cite
Association of TNF-α, IFN-γ, IL-6, and IL-10 with different clinical manifestations of hepatitis B infection. (2023). Italian Journal of Medicine, 17(2). https://doi.org/10.4081/itjm.2023.1627
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.